{
  "docId": "019de074-dee8-7497-a5f7-ae2745d7f9f6",
  "docSlug": "87d7e2eb7c56e30923dbf29903df5034",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 40,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 88,
  "notes": "Includes footnotes regarding clinical trial context for hypertension and cytopenia.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-dee8-7497-a5f7-ae2745d7f9f6/13",
  "deckHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6",
  "deckJsonHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6.json",
  "deckAnchorHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.72,
        "x": 0.14,
        "y": 0.89
      },
      "kind": "disclaimer",
      "text": "* In clinical trials of bevacizumab, incidence of Grade 3-4 hypertension ranged between 5%-18% (Avastin label). It is typically managed by anti-hypertensive drugs\n**Labeled Grade 3/4 cytopenia events for concomitant chemotherapy agent: Irinotecan: 31.4% neutropenia, 4.5% anemia, 1.7% thrombocytopenia. Paclitaxel: 52% neutropenia, 16% anemia, 7% thrombocytopenia",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b976dbc7-1cc0-4a35-a97b-b29e2ecad97e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.46,
        "x": 0.505,
        "y": 0.165
      },
      "kind": "table",
      "text": "Phase 1b Combination (n=17) table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f49c170-783e-4b00-96ac-528d143449dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.58,
        "w": 0.43,
        "x": 0.035,
        "y": 0.165
      },
      "kind": "table",
      "text": "Phase 1a Monotherapy (n=45) table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66a5bb5f-ad11-4207-866b-30d93c05eec6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.43,
        "x": 0.035,
        "y": 0.07
      },
      "kind": "title",
      "text": "Phase 1 CTX-009 Safety Data",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7c17b00-a6b7-4750-97e4-6ad70e892b58",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 14,
      "from": 9,
      "name": "Hypothesis Test",
      "slug": "42-hypothesis-test",
      "bestFor": "Strategy validation, due diligence, research presentations",
      "matchId": "0ddd5348-b518-4772-b40b-b747485bcc63",
      "evidence": "slides 9-14",
      "position": 2,
      "objective": "Present Phase 1 CTX-009 data",
      "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
      "confidence": 0.6,
      "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}